PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25321478-0	2014	Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib.	cabozantinib	92-104	met proto-oncogene	Mus musculus	14-19	
25321478-8	2014	Cabozantinib, an inhibitor of c-Met in phase II trials, eliminated CSC features with a higher therapeutic effect than standard chemotherapy.	cabozantinib	0-12	met proto-oncogene	Mus musculus	30-35	
25321478-9	2014	This study identifies a c-Met(+) tumorigenic sub-population within stromal GCTB cells and suggests the c-Met inhibitor cabozantinib as a new therapeutic option for targeted elimination of unresectable or recurrent GCTB.	cabozantinib	119-131	met proto-oncogene	Mus musculus	24-29	
25321478-9	2014	This study identifies a c-Met(+) tumorigenic sub-population within stromal GCTB cells and suggests the c-Met inhibitor cabozantinib as a new therapeutic option for targeted elimination of unresectable or recurrent GCTB.	cabozantinib	119-131	met proto-oncogene	Mus musculus	103-108